Company profile
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc.

Pipeline6 assets

  • cemacabtagene ansegedleucelcema-cel; ALLO-501A / CD19 / Allogeneic CAR T cell therapy / Hematologic malignancies
    Large B-cell lymphoma, MRD-positive first-line consolidationPivotal Phase 2EnrollingUSCanadaSouth KoreaAustralia
  • ALLO-316ALLO-316 / CD70 / Allogeneic CAR T cell therapy / Solid tumors; hematologic malignancies
    Advanced/metastatic clear cell renal cell carcinomaPhase 1bExpansion cohort enrollment completed; strategic opportunities being exploredCD70+ hematologic malignanciesIND-enablingCD70+ solid tumorsIND-enabling
  • ALLO-329ALLO-329 / CD19/CD70 / Allogeneic dual CAR T cell therapy; CRISPR gene-edited; Dagger technology / Autoimmune disease
    Systemic lupus erythematosus including lupus nephritisPhase 1OngoingIdiopathic inflammatory myopathiesPhase 1OngoingSystemic sclerosisPhase 1Ongoing
  • ALLO-213ALLO-213 / DLL3 / Allogeneic CAR T cell therapy / Solid tumors
    Small cell lung cancerIND-enabling
  • ALLO-182ALLO-182 / Claudin 18.2 / Allogeneic CAR T cell therapy / Solid tumors
    Gastric and pancreatic solid tumorsIND-enabling
  • BCMA/CD70 dual CAR T constructBCMA/CD70 / Allogeneic dual CAR T cell therapy; Dagger technology / Hematologic malignancies
    Multiple myelomaPreclinical

Latest news14 items

All news

Allogene Therapeutics Announces Planned CEO Succession

David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of Directors Zachary Roberts, M.D., Ph.D., EVP, Research & Development and Chief Medical Officer, Appointed President and Chief

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL) 58.3% (7/12) of Patients in the Cema-Cel Arm Achieved Minimal Residual Disease (MRD)

Interim Data • Phase 2Interim data Wed, May 13, 2026

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Study Highlights Dagger ® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in Pre-Clinical Models Dual CD19/CD70 CAR T Cells Rapidly Eliminated B and T Cells in Systemic Lupus

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30% MRD Reduction Occurred Rapidly Following Cema-Cel Treatment with a 97.7% Median Decrease in Plasma ctDNA at Day 45 Compared to a 26.6% Median Increase in the

Interim Data • Phase 2

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the Company will host a

Results Call • Phase 2
Allogene Therapeutics, Inc. • Endpoint Arena